Fol. Biol. 2021, 67, 1-9
https://doi.org/10.14712/fb2021067010001
Questioning How to Define the “Ultra-High-Risk” Subgroup of Neuroblastoma Patients
Crossref Cited-by Linking
- Wang Haoru, Chen Xin, Li Ting, Xie Mingye, Qin Jinjie, Zhang Li, Ding Hao, He Ling: Identification of an Ultra-High-Risk Subgroup of Neuroblastoma Patients within the High-Risk Cohort Using a Computed Tomography-Based Radiomics Approach. Academic Radiology 2024, 31, 1655. <https://doi.org/10.1016/j.acra.2023.08.022>
- Bruinsma Rixt S., Fiocco Marta F., de Leng Wendy W. J., Kester Lennart A., Langenberg Karin P. S., Tytgat Godelieve A. M., van Noesel Max M., Wijnen Marc H. W. A., van der Steeg Alida F. W., de Krijger Ronald R.: mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression. JMP 2024, 5, 304. <https://doi.org/10.3390/jmp5030022>
- Akta\u015f Tekincan Ça\u011fr\u0131, K\u0131zmazo\u011flu Deniz, Akta\u015f Safiye, Gökbayrak Özde Elif, Serinan Efe, Erol Aylin, Altun Zekiye, Yuan Hongling, Olgun Hatice Nur: Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity. Technol Cancer Res Treat 2023, 22. <https://doi.org/10.1177/15330338231211138>
- DEMİR Ayse Banu, ALTUN Zekiye, AKTAŞ Safiye, OLGUN Nur: More Abundant Superoxide Dismutase2 Protein Levels in Blood May Act as a Prognostic Marker for High-Risk Neuroblastoma Patients. Journal of Basic and Clinical Health Sciences 2023, 7, 196. <https://doi.org/10.30621/jbachs.1071115>
- Aktaş Tekincan Çağrı, Aktaş Safiye, Serinan Efe Özgür, Erçetin Pınar, Aydın Melek, Gökbayrak Özde Elif, Erol Aylin, Altun Zekiye, Olgun Nur: Molecular Heterogeneity in Neuroblastoma and Its Clinical Significance. buchd 2023, 13, 123. <https://doi.org/10.4274/buchd.galenos.2023.14238>